Gene Therapies: Bluebird Bio Presses US FDA To Reverse Denial Of Lyfgenia Priority Review Voucher

 
• By Sue Sutter
  
U-Turn Sign
Bluebird bio wants the FDA to reverse its decision denying the company a priority review voucher. (Shutterstock)

More from Cell & Gene Therapies

More from Geography